Glaxo Smith Kline’s antibiotic medication Augmentin and USV’s anti-diabetes drug Glycomet GP maintain their dominance in sales within the Indian pharmaceutical market.
Augmentin from Glaxo Smith Kline and Glycomet GP from USV Pharmaceuticals remain at the forefront of sales in the Indian pharmaceutical sector.
In February, the Indian pharmaceutical market experienced a significant 9 percent rise in value, with key therapeutic categories displaying favorable growth patterns.
Data from research firm PharmaTrac reveals that in February, cardiac, anti-infective, and anti-neoplastic systems demonstrated significant volume growth in the Indian pharmaceutical market. However, the respiratory segment faced a slowdown following a winter surge, reporting a -11.7 percent decline in unit growth rate for February 2024.
Sheetal Sapale, Vice President-Commercial at PharmaTrac, commented, “New product launches and pricing strategies contributed to the positive growth in February, although volume growth remained minimal.”
The Indian pharmaceutical market witnessed a modest unit growth of 0.2 percent in February, presenting challenges across various therapy areas.
Glaxo Smith Kline’s Augmentin and USV’s Glycomet GP maintained their positions as the top-selling medicine brands. Augmentin generated sales of Rs 77 crore in February, accumulating total sales of Rs 822 crore between February 2023 and February 2024. Meanwhile, Glycomet GP achieved sales of Rs 66 crore in February 2024 and Rs 785 crore from February 2023.
In February, Mankind’s Manforce condom brand reclaimed its third position, achieving a Moving Annual Total (MAT) growth rate of 5.2 percent. The brand recorded sales of Rs 57 crore in February 2024, displacing Cipla’s Foracort inhaler as the respiratory segment began to slow down.
Abbott’s Type 2 diabetes/weight management drug Rybelsus showcased an impressive triple-digit value growth rate of 118.5 percent and a unit growth rate of 115 percent. Sales for Rybelsus reached Rs 34 crore in February 2024, with Sapale highlighting, “This brand has consistently maintained robust growth over the past several months.”